TORONTO, May 2, 2019 /CNW/ - Bill Radvak, Executive Chairman, NervGen Pharma Corp. (NGEN), joined Tim Babcock, Managing Director, Capital Formation, TSX Venture Exchange, to open the market. NervGen is a regenerative medicine company dedicated to the advancement of innovative therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. NervGen Pharma Corp. commenced trading on TSX Venture Exchange on March 13, 2019.
SOURCE TMX Group Limited
Share this article